Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

Proteolytic cleavage of nucleocapsid helps SARS-CoV-2 evade host immune responses

A team of scientists of the University of Oxford reveals that the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) undergoes autoproteolysis, and that resulting products can escape the host immune responses and facilitate viral proliferation. The study is currently available on the bioRxiv preprint server.

7 Oct 2020

SARS-CoV-2 spike protein may induce analgesia

A recent study published in the journal Pain in October 2020 adds another piece to the puzzle, showing that the virus is capable of dulling pain pathways. This may contribute to its early and extensive spread.

7 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Researchers in the United States and Canada have discovered a monoclonal antibody that potently neutralizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

5 Oct 2020

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.

5 Oct 2020

Researchers identify a potential target for small cell lung cancer

The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.

1 Oct 2020

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19.

22 Sep 2020

Targeted treatment for systemic lupus erythematosus

A team of researchers from Charité - Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus.

22 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

Ceftazidime flagged as a potential inhibitor of the SARS-COV-2 virus

After screening more than 3,500 FDA-approved drugs and small molecules, researchers at the Chinese Academy of Sciences found that ceftazidime, an antibiotic approved for use in treating pneumonia, binds to the receptors that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in human cells.

17 Sep 2020

Candidate monoclonal antibody shows hope as COVID-19 treatment

Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Sep 2020

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

Prostate cancer is the most common type of cancer among European men; its incidence surpasses 100 cases per 100,000 people.

15 Sep 2020

UChicago Medicine launches clinical trial to test the potential of antibody against SARS-CoV-2

The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.

3 Sep 2020

VUMC launches clinical trial of promising COVID-19 treatments in outpatient setting

Vanderbilt University Medical Center is launching a clinical trial of promising treatments for COVID-19 in the outpatient setting.

2 Sep 2020

Study identifies effective treatment for severe COVID-19 patients

As countries around the world race to develop a vaccine for SARS-CoV-2, the virus responsible for COVID-19, researchers are working to understand exactly how it causes the myriad of symptoms that seem to linger long after active viral infection.

31 Aug 2020

IL-6 signaling blockade can alleviate severe COVID-19

A team of researchers led by Osaka University find an overlap in the pathogenesis of cytokine release syndrome and COVID-19, and show that the symptoms of both can be alleviated by IL-6 signaling blockade

31 Aug 2020

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.

25 Aug 2020

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

A new study by researchers at MassBiologics of UMass Medical School published in Nature Communications suggests that COVID specific IgA monoclonal antibodies may provide effective immunity in the respiratory system against the novel coronavirus - a potentially critical feature of an effective vaccine.

25 Aug 2020

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU).

20 Aug 2020

Monoclonal Antibody News and Research

Further Reading

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Proteolytic cleavage of nucleocapsid helps SARS-CoV-2 evade host immune responses

SARS-CoV-2 spike protein may induce analgesia

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Researchers identify a potential target for small cell lung cancer

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

Targeted treatment for systemic lupus erythematosus

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

Ceftazidime flagged as a potential inhibitor of the SARS-COV-2 virus

Candidate monoclonal antibody shows hope as COVID-19 treatment

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

UChicago Medicine launches clinical trial to test the potential of antibody against SARS-CoV-2

VUMC launches clinical trial of promising COVID-19 treatments in outpatient setting

Study identifies effective treatment for severe COVID-19 patients

IL-6 signaling blockade can alleviate severe COVID-19

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®